CTLA4 and neoplasm: C57BL/6 J mice bearing RIPK3−/− melanomas showed diminished tumor control and poor survival when undergoing combined therapy with anti-PD-1 and anti-CTLA-4 (figure 2A–C and online supplemental figure S3A).